|
| Status |
Public on May 03, 2024 |
| Title |
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response [Tru-seq] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
To investigate the transcriptomic changes associated with KRAS G12C inhibitor Adagrasib resistance and Adagrasib + SOS1 inhibitor (BI-3406) or Adagrasib + EGFR inhibitor (Cetuximab) combination treatment to overcome resistance. We performed differential gene expression analysis using RNA-seq generated from cell line derived xenograft (CDX) in vivo models. We compared different treatment conditions with DMSO treated condition.
|
| |
|
| Overall design |
CDX models were generated using NSCLC cell line NCI-H2122. For each CDX category, expression data with Natrosol treated and either single agent and combination treatment was generated.
|
| |
|
| Contributor(s) |
Thatikonda V, Gerlach D, Bergner O, Alpar D, Hofmann M, Kamuda M |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Feb 15, 2024 |
| Last update date |
May 04, 2024 |
| Contact name |
Daniel Gerlach |
| E-mail(s) |
daniel.gerlach@boehringer-ingelheim.com
|
| Organization name |
Boehringer Ingelheim RCV GmbH & Co KG
|
| Department |
Global Computational Biology and Digital Sciences
|
| Street address |
Dr.-Boehringer-Gasse 5-11
|
| City |
Vienna |
| ZIP/Postal code |
1121 |
| Country |
Austria |
| |
|
| Platforms (1) |
|
| Samples (22)
|
|
| This SubSeries is part of SuperSeries: |
| GSE225061 |
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response |
|
| Relations |
| BioProject |
PRJNA1076862 |
Less...
More...